Multiple sclerosis
Immune-modulating mesenchymal stem cell protocols for relapsing-remitting and progressive MS — used alongside disease-modifying therapy. Recent meta-analyses show significant reductions in EDSS disability scores and durable shifts in immune cell populations.
- Class
- Autoimmune CNS
- Approach
- IV systemic / intrathecal
- Materials
- MSC · MSC-NP · exosome
- Coordination
- With neurology
01 About
What MS is.
Multiple sclerosis is an autoimmune disease in which the body's immune system attacks the myelin sheaths surrounding nerve fibers in the central nervous system. The damage manifests as relapses (relapsing-remitting MS) or as gradual decline (primary or secondary progressive MS). Standard treatment is disease-modifying therapy (DMT) — interferons, monoclonal antibodies, oral immunosuppressants — to reduce relapse frequency and slow progression.
Stem cell therapy is being studied as an immune-modulating addition to DMT. The intended mechanism aligns directly with the disease mechanism: MSCs broadly modulate immune response and reduce inflammation. The clinical question is whether that translates into measurable disease-course modification.
02 How it works
How regen supports MS.
Mesenchymal stem cells administered intravenously or intrathecally exert broad immunomodulatory effects: they reduce activation of autoreactive T cells, increase regulatory T cell populations, and reduce proinflammatory cytokine release. Some evidence suggests neurotrophic effects on damaged tissue, though the strongest signal is on the immune side.
This is one of the indications where it is most important to be clear: stem cell therapy is not a replacement for DMT. Patients should continue their MS specialist's recommended therapy. Regen sits alongside as an immune-modulating adjunct — not as a substitute for evidence-based MS treatment.
03 What the research shows
What the studies show.
The MS evidence base has matured substantially in the last few years. Pooled clinical-trial data shows significant reductions in EDSS disability, durable immune-cell rebalancing, and improvements in cognitive and functional measures — particularly with intrathecal and repeated-dosing protocols.
Neurological Efficacy and Safety of MSC Therapy in People with MS
A 2024 systematic review and meta-analysis of 30 studies of MSC therapy in MS demonstrated significant improvement in EDSS disability scores (weighted mean difference −0.28, p = 0.028) — a meaningful disability reduction. The strongest signal was in intrathecally-treated patients. Safety was consistent across the included trials.
Read on MSARDLong-Term Effects of Repeated MSC Injections in Progressive MS
A long-term study of repeated MSC injections in progressive MS showed sustained reductions in EDSS scores (P < 0.0001), cognitive and psychological improvements, and meaningful changes in DTI imaging metrics over 6 months. Pro-inflammatory cytokines (TNF-α, IL-6, IL-17) decreased significantly while anti-inflammatory IL-10 rose — durable mechanistic shift.
Read on FrontiersStem Cell Transplantation for MS: Systematic Review and Meta-Analysis of RCTs
A 2024 meta-analysis of randomized controlled trials of stem cell transplantation in MS confirmed safety and demonstrated meaningful clinical benefit on disability progression and functional outcomes — supporting MSC therapy as a reasoned addition to disease-modifying therapy.
Read on Nature
The MS field has shifted from "promising mechanism" to "documented disability reduction" in the last 24 months. We position regen as adjunctive to DMT — designed to broaden the immune-rebalancing effect, not to replace established therapy.
04 Are you a candidate
Who's a candidate.
Candidates:
- Relapsing-remitting MS or progressive MS with persistent disease activity despite DMT.
- Patients on appropriate disease-modifying therapy with their MS specialist.
- Stable medical status with realistic expectations about adjunctive benefit.
- Patients seeking to broaden the immune-modulation profile of their treatment.
When we will not recommend it:
- Patients seeking to discontinue DMT — we will not facilitate that.
- Active CNS or systemic infection.
- Pregnancy or planning pregnancy in the immediate future.
- Patients without a confirmed MS diagnosis from a neurologist.
Think you might be a candidate?
The first step is a 60–90 minute consultation. We review your imaging, history, and goals — and tell you honestly whether regenerative therapy is the right next step.
05 A patient experience
Dr. Abdullah did an amazing job treating both me and my spouse. I feel less pain every day, and my brain fog is entirely gone. It's only been about 3 weeks.
Kayla Google · Local Guide
07What happens at your consultation
A conversation, not a sales meeting.
-
01
Intake & history
60–90 minutes. We review imaging, prior treatments, current medications, and goals. Most of this hour is listening.
-
02
Focused exam
A clinical exam tailored to your indication. Range of motion, strength, functional testing — what the literature actually predicts response on.
-
03
Honest candidacy review
If we think you're a candidate, we'll tell you why. If we don't, we'll tell you what we'd recommend instead — surgery, PT, watchful waiting.
-
04
Written plan & pricing
A defined treatment plan with modality, sequence, follow-up cadence, and total cost — before any commitment.
06 What treatment looks like
What treatment looks like.
A typical MS protocol begins with consultation, neurology coordination, and review of disease history, MRI, and current DMT. Treatment is typically IV systemic MSC and/or exosome material in a series spaced over weeks to months. We do not perform intrathecal injections in our clinic — those remain in clinical-trial settings.
Reassessment at 3, 6, and 12 months. Symptom tracking, repeat MRI when appropriate, and ongoing coordination with the MS neurologist.
09 Common questions
Common questions, answered.
Should I stop my DMT?
No. We never recommend discontinuing disease-modifying therapy. Regenerative therapy sits alongside DMT.
Can this slow MS progression?
Recent meta-analyses show significant EDSS disability reduction across pooled trials. We're explicit about realistic expectations and patient subgroups.
Does this work for primary progressive MS?
Phase II intrathecal-protocol data suggests yes. We discuss the specifics for your subtype during consultation.
Will I need ongoing maintenance?
Often yes — repeated dosing produces stronger signals than single doses in the published literature.
Is this safe with my biologic therapy?
Generally yes. We coordinate with your neurologist before scheduling any protocol.
What are the risks?
Safety has been consistently demonstrated across MS trials. Mild post-infusion fatigue or headache is the most common minor effect.
08 Coverage & cost
Most regenerative protocols at Apex are not covered by insurance — we discuss pricing directly, in writing, before any commitment. Softwave shockwave is the exception: covered by Medicare Parts A & B with supplement (not by Medicare Advantage). Financing options are available for protocols not covered. We never hold a pricing conversation until we know you're a candidate.
Begin with a consultation.
A frank conversation about your MS, your DMT, and whether regenerative therapy is the right adjunct — and what realistic expectations look like.